CAJ | 학술논문

目的:探讨恶性肿瘤患者血清胱抑素C(Cystatin C)和可溶性尿激酶受体(suPAR)水平与肿瘤浸润转移和治疗的关系.方法:Cystatin C应用颗粒增强散射免疫比浊法(PENIA)检测;suPAR采用ELISA法检测.共检测了82例健康成人和172例恶性肿瘤患者血清Cystatin C和suPAR水平并进行比较.结果:恶性肿瘤患者血清Cystatin C和suPAR水平较健康对照组显著增高(P＜0.01和P＜0.01),差异有显著性;中晚期、已转移组的肿瘤患者Cystatin C和suPAR测定值均显著高于各自对照组;在治疗过程中,患者血清Cystatin C和suPAR水平,术后与术前比较,两组指标均明显降低,但接受化疗及放疗的患者,血清Cystatin C和suPAR水平与治疗与否无差异.结论:恶性肿瘤患者血清Cystatin C和suPAR水平与肿瘤细胞的浸润转移以及手术治疗有关.检测血清Cystatin C和suPAR水平对恶性肿瘤患者的病情监测和疗效判断有重要的临床价值.
목적:탐토악성종류환자혈청광억소C(Cystatin C)화가용성뇨격매수체(suPAR)수평여종류침윤전이화치료적관계.방법:Cystatin C응용과립증강산사면역비탁법(PENIA)검측;suPAR채용ELISA법검측.공검측료82례건강성인화172례악성종류환자혈청Cystatin C화suPAR수평병진행비교.결과:악성종류환자혈청Cystatin C화suPAR수평교건강대조조현저증고(P＜0.01화P＜0.01),차이유현저성;중만기、이전이조적종류환자Cystatin C화suPAR측정치균현저고우각자대조조;재치료과정중,환자혈청Cystatin C화suPAR수평,술후여술전비교,량조지표균명현강저,단접수화료급방료적환자,혈청Cystatin C화suPAR수평여치료여부무차이.결론:악성종류환자혈청Cystatin C화suPAR수평여종류세포적침윤전이이급수술치료유관.검측혈청Cystatin C화suPAR수평대악성종류환자적병정감측화료효판단유중요적림상개치.
Objective To explore the relationship of serum level of Cystatin C and suPAR with tumor infiltration, metastasis, and treatment of patients with malignant tumor. Methods: The serum levels of Cystatin C was detected by particle enhanced nephelometic immunoassay (PENIA) by 7600-010 full-automatic biochemical analyzer made in Japan. The level of suPAR was detected by ELISA. The serum levels of Cystatin C and suPARof 82 normal adults and 172 patients with malignant tumor were measured and compared. Results: The serum level of Cystatin C and suPAR in patients with malignant tumor was significantly increased compared with that of normal adults (P＜0.01 and P＜0.01). The level of Cystatin C and suPAR in terminally ill patients or patients with metastasis was significantly higher than that in the control group. The levels of the two indices in postoperative patients were lower than those in preoperative patients. No significant difference was found in the levels of the two indicies before chemotherapy or radiotherapy and after therapy. Conclusion: The serum levels of Cystatin C and suPARin patients with malignant tumor are correlated with tumor invasion, metastasis and surgical intervention. Detection of Cystatin C and suPAR levels in patients with malignant tumor is valuable for disease monitoring and treatment evaluation.